Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis
- PMID: 34341424
- PMCID: PMC8329155
- DOI: 10.1038/s41598-021-95065-9
Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis
Abstract
Multiple factors regulate glucagon-like peptide-1 (GLP-1) secretion, but a group of apparently healthy subjects showed blunted responses of GLP-1 secretion in our previous study. In this study, we examined whether the reduction in GLP-1 secretory capacity is associated with increased extent of coronary artery stenosis in non-diabetic patients. Non-diabetic patients who were admitted for coronary angiography without a history of coronary interventions were enrolled. Coronary artery stenosis was quantified by Gensini score (GS), and GS ≥ 10 was used as an outcome variable based on its predictive value for cardiovascular events. The patients (mean age, 66.5 ± 8.8 years; 71% males, n = 173) underwent oral 75 g-glucose tolerant tests for determination of glucose, insulin and active GLP-1 levels. The area under the curve of plasma active GLP-1 (AUC-GLP-1) was determined as an index of GLP-1 secretory capacity. AUC-GLP-1 was not correlated with fasting glucose, AUC-glucose, serum lipids or indices of insulin sensitivity. In multivariate logistic regression analysis for GS ≥ 10, AUC-GLP-1 < median, age and hypertension were selected as explanatory variables, though fasting GLP-1 level was not selected. The findings suggest that reduction in GLP-1 secretory capacity is a novel independent risk factor of coronary stenosis.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.PLoS One. 2013 Jul 2;8(7):e67578. doi: 10.1371/journal.pone.0067578. Print 2013. PLoS One. 2013. PMID: 23844037 Free PMC article.
-
Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.Eur J Endocrinol. 1996 Oct;135(4):425-32. doi: 10.1530/eje.0.1350425. Eur J Endocrinol. 1996. PMID: 8921824
-
Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.Diabetes. 2001 Apr;50(4):776-84. doi: 10.2337/diabetes.50.4.776. Diabetes. 2001. PMID: 11289042 Clinical Trial.
-
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?Diabetologia. 2011 Jan;54(1):10-8. doi: 10.1007/s00125-010-1896-4. Epub 2010 Sep 25. Diabetologia. 2011. PMID: 20871975 Review.
-
Glucagon-like peptide 1 (GLP-1) and metabolic diseases.J Endocrinol Invest. 2005 Sep;28(8):746-58. doi: 10.1007/BF03347560. J Endocrinol Invest. 2005. PMID: 16277173 Review.
Cited by
-
Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.Diabetes Ther. 2025 May;16(5):993-1017. doi: 10.1007/s13300-025-01724-9. Epub 2025 Mar 24. Diabetes Ther. 2025. PMID: 40126828 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources